Federal research mandate for Down syndrome expands clinical trials and care
S. 1838 — DeOndra Dixon INCLUDE Project Act of 2026 · Filed by John Hickenlooper (D-CO) · 9 cosponsors · Introduced May 21, 2025 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the National Institutes of Health (NIH) to establish and carry out a coordinated research program on Down syndrome, called the INCLUDE Project, focusing on the condition's effects on development, co-occurring health conditions (like Alzheimer's and autoimmunity), clinical trials, quality of life, and improved diagnosis and treatment. The NIH must report biennially to Congress on research conducted and coordinate across its institutes to avoid duplication.
Why we flagged it
The bill's operative mechanism is a straightforward authorization for NIH to conduct and coordinate Down syndrome research across its institutes, with mandatory reporting. It is a public-health research program, not a commemorative measure—the naming after DeOndra Dixon (a Down syndrome advocate) reflects the bill's beneficiary population and legislative inspiration, not vanity.
What the text implies
- Biennial reporting requirement creates ongoing congressional oversight and public accountability for NIH Down syndrome research priorities and outcomes.
- Coordination mandate across NIH institutes may shift internal resource allocation and priority-setting, potentially affecting other research areas.
- Explicit inclusion of co-occurring conditions (Alzheimer's, autoimmunity) in research scope may generate secondary benefits for understanding these conditions in the broader population.
- Requirement to consult with patient advocates and stakeholders embeds disability-community voice in federal research governance.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill establishes a coordinated, federally-funded research program addressing a genetic condition affecting approximately 250,000 Americans, with explicit focus on improving diagnosis, treatment, quality of life, and understanding of co-occurring conditions. Citizens with Down syndrome and their families gain access to expanded research infrastructure, clinical trial participation, and evidence-based interventions, while the biennial reporting requirement creates public accountability for res
Who stands to gain
- National Institutes of Health (federal research funding)
- Academic medical centers and research institutions (NIH grant recipients)
- Biomedical research contractors and clinical trial sponsors
Named in the bill
National Institutes of Health (NIH), NIH Director, Office of the Director of NIH, Committee on Energy and Commerce (House), Committee on Health, Education, Labor, and Pensions (Senate), Subcommittee on Labor, Health and Human Services, Education, and Related Agencies (both chambers), Down syndrome patient advocates and stakeholders
Where it stands
9 cosponsors: 6 Democrats, 3 Republicans.
- May 21, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- May 21, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
- Aug 6, 2026 — Reported out of committee · Congress.gov: “Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent”
- Aug 6, 2026 — Passed the Senate · Congress.gov: “Passed Senate with an amendment by Voice Vote. (text of amendment in the nature of a substitute: CR…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
13 lobbying clients named this bill on 19 disclosure filings across 3 quarters, Jun 2025 to Jun 2026. Those filings disclosed $8,280,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 94% of bills with at least one filing.
John Hickenlooper, the sponsor, reported $975,352 in PAC receipts in the 2026 cycle.
- Alzheimer's Association — $3,590,000 on 2 filings
- Electronic Payments Coalition Inc. — $2,820,000 on 1 filing
- Bank Policy Institute — $1,130,000 on 2 filings
- Electronic Payments Coalition — $220,000 on 2 filings
- National Association of Convenience Stores — $160,000 on 2 filings
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (3,842 characters) on Aug 7, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Federal research mandate for Down syndrome expands clinical trials and care” QuorumCivic. https://share.quorumcivic.app/bill/119/s1838 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.